{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:25:07Z","timestamp":1784823907310,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,10,6]],"date-time":"2016-10-06T00:00:00Z","timestamp":1475712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1038\/bjc.2016.318","type":"journal-article","created":{"date-parts":[[2016,10,6]],"date-time":"2016-10-06T22:54:44Z","timestamp":1475794484000},"page":"1193-1200","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases \u2013 results and lessons learnt"],"prefix":"10.1038","volume":"115","author":[{"given":"Avinash","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corran","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Tysoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Goff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Nobes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernie","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carie","family":"Corner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Wolstenholme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelyn","family":"Wise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Love","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Salisbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R","family":"Middleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,6]]},"reference":[{"key":"BFbjc2016318_CR1","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1200\/JCO.2004.11.044","volume":"22","author":"SS Agarwala","year":"2004","unstructured":"Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N, Czarnetski B, Atkins M, Buzaid A, Skarlos D, Rankin EM (2004) Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 22: 2101\u20132107.","journal-title":"J Clin Oncol"},{"key":"BFbjc2016318_CR2","doi-asserted-by":"publisher","first-page":"e486","DOI":"10.1016\/S1470-2045(15)00141-2","volume":"16","author":"T Ajithkumar","year":"2015","unstructured":"Ajithkumar T, Parkinson C, Fife K, Corrie P, Jefferies S (2015) Evolving treatment options for melanoma brain metastases. Lancet Oncol 16: e486\u2013e497.","journal-title":"Lancet Oncol"},{"key":"BFbjc2016318_CR3","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1002\/cncr.23805","volume":"113","author":"MB Atkins","year":"2008","unstructured":"Atkins MB, Sosman JA, Agarwala S, Logan T, Clark JI, Ernstoff MS, Lawson D, Dutcher JP, Weiss G, Curti B, Margolin KA (2008) Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer 113: 2139\u20132145.","journal-title":"Cancer"},{"issue":"7","key":"BFbjc2016318_CR4","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/nrclinonc.2016.19","volume":"13","author":"KC Bible","year":"2016","unstructured":"Bible KC, Ryder M (2016) Evolving molecularly targeted therapies for advanced-stage thyroid cancers. Nat Rev Clin Oncol 13 (7): 403\u2013416.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFbjc2016318_CR5","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.1158\/1078-0432.CCR-13-3003","volume":"20","author":"G Chen","year":"2014","unstructured":"Chen G, Chakravarti N, Aardalen K, Lazar AJ, Tetzlaff MT, Wubbenhorst B, Kim SB, Kopetz S, Ledoux AA, Gopal YN, Pereira CG, Deng W, Lee JS, Nathanson KL, Aldape KD, Prieto VG, Stuart D, Davies MA (2014) Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. Clin Cancer Res 20: 5537\u20135546.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2016318_CR6","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s13014-015-0553-y","volume":"10","author":"IH Chowdhury","year":"2015","unstructured":"Chowdhury IH, Ojerholm E, Mcmillan MT, Miller D, Kolker JD, Kurtz G, Dorsey JF, Nagda SN, Geiger GA, Brem S, O\u2019Rourke DM, Zager EL, Gangadhar T, Schuchter L, Lee JY, Alonso-Basanta M (2015) Novel risk scores for survival and intracranial failure in patients treated with radiosurgery alone to melanoma brain metastases. Radiat Oncol 10: 248.","journal-title":"Radiat Oncol"},{"key":"BFbjc2016318_CR7","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3816\/CLC.2010.n.022","volume":"11","author":"D Chua","year":"2010","unstructured":"Chua D, Krzakowski M, Chouaid C, Pallotta MG, Martinez JI, Gottfried M, Curran W, Throuvalas N (2010) Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study. Clin Lung Cancer 11: 176\u2013181.","journal-title":"Clin Lung Cancer"},{"key":"BFbjc2016318_CR8","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1002\/cncr.25634","volume":"117","author":"MA Davies","year":"2011","unstructured":"Davies MA, Liu P, Mcintyre S, Kim KB, Papadopoulos N, Hwu WJ, Hwu P, Bedikian A (2011) Prognostic factors for survival in melanoma patients with brain metastases. Cancer 117: 1687\u20131696.","journal-title":"Cancer"},{"key":"BFbjc2016318_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ijrobp.2009.07.1741","volume":"78","author":"J Drappatz","year":"2010","unstructured":"Drappatz J, Norden AD, Wong ET, Doherty LM, Lafrankie DC, Ciampa A, Kesari S, Sceppa C, Gerard M, Phan P, Schiff D, Batchelor TT, Ligon KL, Young G, Muzikansky A, Weiss SE, Wen PY (2010) Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys 78: 85\u201390.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BFbjc2016318_CR10","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ejca.2013.11.002","volume":"50","author":"R Dummer","year":"2014","unstructured":"Dummer R, Goldinger SM, Turtschi CP, Eggmann NB, Michielin O, Mitchell L, Veronese L, Hilfiker PR, Felderer L, Rinderknecht JD (2014) Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 50: 611\u2013621.","journal-title":"Eur J Cancer"},{"key":"BFbjc2016318_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228\u2013247.","journal-title":"Eur J Cancer"},{"key":"BFbjc2016318_CR12","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1200\/JCO.2004.08.140","volume":"22","author":"KM Fife","year":"2004","unstructured":"Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, Harman R, Petersen-Schaefer K, Zacest AC, Besser M, Milton GW, McCarthy WH, Thompson JF (2004) Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 22: 1293\u20131300.","journal-title":"J Clin Oncol"},{"key":"BFbjc2016318_CR13","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/1471-2407-11-142","volume":"11","author":"G Fogarty","year":"2011","unstructured":"Fogarty G, Morton RL, Vardy J, Nowak AK, Mandel C, Forder PM, Hong A, Hruby G, Burmeister B, Shivalingam B, Dhillon H, Thompson JF (2011) Whole brain radiotherapy after local treatment of brain metastases in melanoma patients\u2014a randomised phase III trial. BMC Cancer 11: 142.","journal-title":"BMC Cancer"},{"key":"BFbjc2016318_CR14","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1186\/1756-0500-7-412","volume":"7","author":"GB Fogarty","year":"2014","unstructured":"Fogarty GB, Hong A, Jacobsen KD, Reisse CH, Shivalingam B, Burmeister B, Haydu LE, Paton E, Thompson JF (2014) Accrual to a randomised trial of adjuvant whole brain radiotherapy for treatment of melanoma brain metastases is feasible. BMC Res Notes 7: 412.","journal-title":"BMC Res Notes"},{"key":"BFbjc2016318_CR15","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S0360-3016(00)00547-2","volume":"47","author":"LE Gaspar","year":"2000","unstructured":"Gaspar LE, Scott C, Murray K, Curran W (2000) Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 47: 1001\u20131006.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BFbjc2016318_CR16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00280-007-0460-5","volume":"61","author":"DL Gustafson","year":"2008","unstructured":"Gustafson DL, Frederick B, Merz AL, Raben D (2008) Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts. Cancer Chemother Pharmacol 61: 179\u2013188.","journal-title":"Cancer Chemother Pharmacol"},{"key":"BFbjc2016318_CR17","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00508-013-0402-7","volume":"125","author":"MR Hassler","year":"2013","unstructured":"Hassler MR, Pfeifer W, Knocke-Abulesz TH, Geissler K, Altorjai G, Dieckmann K, Marosi C (2013) Temozolomide added to whole brain radiotherapy in patients with multiple brain metastases of non-small-cell lung cancer: a multicentric Austrian phase II study. Wien Klin Wochenschr 125: 481\u2013486.","journal-title":"Wien Klin Wochenschr"},{"key":"BFbjc2016318_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11060-005-2914-0","volume":"76","author":"M Hofmann","year":"2006","unstructured":"Hofmann M, Kiecker F, Wurm R, Schlenger L, Budach V, Sterry W, Trefzer U (2006) Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. J Neurooncol 76: 59\u201364.","journal-title":"J Neurooncol"},{"key":"BFbjc2016318_CR19","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1016\/j.ejca.2015.08.022","volume":"51","author":"DB Johnson","year":"2015","unstructured":"Johnson DB, Menzies AM, Zimmer L, Eroglu Z, Ye F, Zhao S, Rizos H, Sucker A, Scolyer RA, Gutzmer R, Gogas H, Kefford RF, Thompson JF, Becker JC, Berking C, Egberts F, Loquai C, Goldinger SM, Pupo GM, Hugo W, Kong X, Garraway LA, Sosman JA, Ribas A, Lo RS, Long GV, Schadendorf D (2015) Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur J Cancer 51: 2792\u20132799.","journal-title":"Eur J Cancer"},{"key":"BFbjc2016318_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ijrobp.2007.09.016","volume":"71","author":"JP Knisely","year":"2008","unstructured":"Knisely JP, Berkey B, Chakravarti A, Yung AW, Curran WJ Jr, Robins HI, Movsas B, Brachman DG, Henderson RH, Mehta MP (2008) A phase III study of conventional radiation therapy plus thalidomide versus conventional radiation therapy for multiple brain metastases (RTOG 0118). Int J Radiat Oncol Biol Phys 71: 79\u201386.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BFbjc2016318_CR21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/CAD.0b013e32834dc279","volume":"23","author":"E Langenkamp","year":"2012","unstructured":"Langenkamp E, Zwiers PJ, Moorlag HE, Leenders WP, St Croix B, Molema G (2012) Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296. Anticancer Drugs 23: 161\u2013172.","journal-title":"Anticancer Drugs"},{"key":"BFbjc2016318_CR22","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/j.clon.2012.11.002","volume":"25","author":"RE Langley","year":"2013","unstructured":"Langley RE, Stephens RJ, Nankivell M, Pugh C, Moore B, Navani N, Wilson P, Faivre-Finn C, Barton R, Parmar MK, Mulvenna PM Investigators, Q. (2013) Interim data from the Medical Research Council QUARTZ Trial: does whole brain radiotherapy affect the survival and quality of life of patients with brain metastases from non-small cell lung cancer? Clin Oncol (R Coll Radiol) 25: e23\u2013e30.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"BFbjc2016318_CR23","doi-asserted-by":"publisher","first-page":"6222","DOI":"10.1158\/1078-0432.CCR-04-0823","volume":"10","author":"WP Leenders","year":"2004","unstructured":"Leenders WP, Kusters B, Verrijp K, Maass C, Wesseling P, Heerschap A, Ruiter D, Ryan A, de Waal R (2004) Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin Cancer Res 10: 6222\u20136230.","journal-title":"Clin Cancer Res"},{"key":"BFbjc2016318_CR24","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","volume":"13","author":"GV Long","year":"2012","unstructured":"Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13: 1087\u20131095.","journal-title":"Lancet Oncol"},{"key":"BFbjc2016318_CR25","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.ijrobp.2008.05.068","volume":"73","author":"MP Mehta","year":"2009","unstructured":"Mehta MP, Shapiro WR, Phan SC, Gervais R, Carrie C, Chabot P, Patchell RA, Glantz MJ, Recht L, Langer C, Sur RK, Roa WH, Mahe MA, Fortin A, Nieder C, Meyers CA, Smith JA, Miller RA, Renschler MF (2009) Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial. Int J Radiat Oncol Biol Phys 73: 1069\u20131076.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BFbjc2016318_CR26","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1634\/theoncologist.2008-0261","volume":"14","author":"A Morabito","year":"2009","unstructured":"Morabito A, Piccirillo MC, Falasconi F, De Feo G, Del Giudice A, Bryce J, Di Maio M, De Maio E, Normanno N, Perrone F (2009) Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist 14: 378\u2013390.","journal-title":"Oncologist"},{"key":"BFbjc2016318_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/00008390-200302000-00016","volume":"13","author":"F Mornex","year":"2003","unstructured":"Mornex F, Thomas L, Mohr P, Hauschild A, Delaunay MM, Lesimple T, Tilgen W, Bui BN, Guillot B, Ulrich J, Bourdin S, Mousseau M, Cupissol D, Bonneterre ME, de Gislain C, Bensadoun RJ, Clavel M (2003) A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma. Melanoma Res 13: 97\u2013103.","journal-title":"Melanoma Res"},{"key":"BFbjc2016318_CR28","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/sj.bjc.6604835","volume":"100","author":"T Neuhaus","year":"2009","unstructured":"Neuhaus T, Ko Y, Muller RP, Grabenbauer GG, Hedde JP, Schueller H, Kocher M, Stier S, Fietkau R (2009) A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. Br J Cancer 100: 291\u2013297.","journal-title":"Br J Cancer"},{"key":"BFbjc2016318_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1634\/theoncologist.2014-0278","volume":"20","author":"P Niravath","year":"2015","unstructured":"Niravath P, Tham YL, Wang T, Rodriguez A, Foreman C, Hilsenbeck SG, Elledge R, Rimawi M (2015) A phase II trial of capecitabine concomitantly with whole-brain radiotherapy followed by capecitabine and sunitinib for brain metastases from breast cancer. Oncologist 20: 13.","journal-title":"Oncologist"},{"issue":"Suppl","key":"BFbjc2016318_CR30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3171\/JNS\/2008\/109\/12\/S16","volume":"109","author":"AJ Redmond","year":"2008","unstructured":"Redmond AJ, Diluna ML, Hebert R, Moliterno JA, Desai R, Knisely JP, Chiang VL (2008) Gamma Knife surgery for the treatment of melanoma metastases: the effect of intratumoral hemorrhage on survival. J Neurosurg 109 (Suppl): 99\u2013105.","journal-title":"J Neurosurg"},{"key":"BFbjc2016318_CR31","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.ijrobp.2013.03.040","volume":"86","author":"HI Robins","year":"2013","unstructured":"Robins HI, O\u2019Neill A, Mehta M, GRossman S (2013) A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT & SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation n Therapy Oncology Group 0320: in regard to Sperduto et al. Int J Radiat Oncol Biol Phys 86: 809\u2013810.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BFbjc2016318_CR32","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.radonc.2006.08.004","volume":"80","author":"DE Roos","year":"2006","unstructured":"Roos DE, Wirth A, Burmeister BH, Spry NA, Drummond KJ, Beresford JA, McClure BE (2006) Whole brain irradiation following surgery or radiosurgery for solitary brain metastases: mature results of a prematurely closed randomized Trans-Tasman Radiation Oncology Group trial (TROG 98.05). Radiother Oncol 80: 318\u2013322.","journal-title":"Radiother Oncol"},{"key":"BFbjc2016318_CR33","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1016\/j.ijrobp.2007.07.2350","volume":"69","author":"K Shibuya","year":"2007","unstructured":"Shibuya K, Komaki R, Shintani T, Itasaka S, Ryan A, Jurgensmeier JM, Milas L, Ang K, Herbst RS, O\u2019Reilly MS (2007) Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 69: 1534\u20131543.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BFbjc2016318_CR34","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/j.ijrobp.2012.11.042","volume":"85","author":"PW Sperduto","year":"2013","unstructured":"Sperduto PW, Wang M, Robins HI, Schell MC, Werner-Wasik M, Komaki R, Souhami L, Buyyounouski MK, Khuntia D, Demas W, Shah SA, Nedzi LA, Perry G, Suh JH, Mehta MP (2013) A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. Int J Radiat Oncol Biol Phys 85: 1312\u20131318.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BFbjc2016318_CR35","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.lungcan.2014.05.012","volume":"85","author":"RJ Stephens","year":"2014","unstructured":"Stephens RJ, Langley RE, Mulvenna P, Nankivell M, Vail A, Parmar MK (2014) Interim results in clinical trials: do we need to keep all interim randomised clinical trial results confidential? Lung Cancer 85: 116\u2013118.","journal-title":"Lung Cancer"},{"key":"BFbjc2016318_CR36","first-page":"4645","volume":"62","author":"SR Wedge","year":"2002","unstructured":"Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ES, Curry B, Richmond GH, Wadsworth PF, Bigley AL, Hennequin LF (2002) ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62: 4645\u20134655.","journal-title":"Cancer Res"},{"key":"BFbjc2016318_CR37","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1200\/JCO.2011.40.1174","volume":"31","author":"JW Welsh","year":"2013","unstructured":"Welsh JW, Komaki R, Amini A, Munsell MF, Unger W, Allen PK, Chang JY, Wefel JS, McGovern SL, Garland LL, Chen SS, Holt J, Liao Z, Brown P, Sulman E, Heymach JV, Kim ES, Stea B (2013) Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 31: 895\u2013902.","journal-title":"J Clin Oncol"},{"key":"BFbjc2016318_CR38","first-page":"49","volume":"3","author":"Y Zang","year":"2014","unstructured":"Zang Y, Lee JJ (2014) Adaptive clinical trial designs in oncology. Chin Clin Oncol 3: 49.","journal-title":"Chin Clin Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2016318.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2016318","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2016318.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T13:34:27Z","timestamp":1684416867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2016318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,6]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["BFbjc2016318"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2016.318","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,6]]},"assertion":[{"value":"4 May 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MRM has consulted for and received research funding from AstraZeneca, GlaxoSmithKline and Roche. All other authors have declared no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}